Sales of Eylea, which the company co-developed with Bayer (DE:BAYA), rose 2% to $1.495 billion. Sales of the higher-dose, longer-lasting formulation Eylea HD rose 148% to $305 million in the U.S., ...

We sifted through stock screeners, online rankings, and ETFs to compile a list of 30 cancer stocks. We then selected the top ...

Regeneron reported Q4 2024 earnings today and declared its first-ever dividend of $0.88 per quarter. Click here to know what ...

The hope is that approach will kill tumour cells but avoid off-target side effects, such as the potentially ... partnered PD-1 checkpoint inhibitor Libtayo (cemiplimab), and the drugmaker has ...

However, CAR-Ts are made from patients’ cells and have complex manufacturing and administration procedures, are associated with higher rates of side effects, such as cytokine release syndrome ...

It sells Libtayo, a cancer drug that recently got approved for a ... without the risk of addiction and fewer side effects. One of the largest pharmaceutical companies in the world, with a total ...

Common risks or side effects of a biopsy procedure that is used to obtain ... pembrolizumab (Keytruda®), atezolizumab (Tecentriq®), and cemiplimab (Libtayo®). Of note, these pharmacological agents ...

Blood thinners prescribed after blood clots in the leg or lung initially increase the risk of bleeding, especially in women ...